Davita - Hioaks Dialysis is a medicare approved dialysis facility center in Richmond, Virginia and it has 16 dialysis stations. It is located in Richmond City county at 671 Hioaks Rd, Richmond, VA, 23225. You can reach out to the office of Davita - Hioaks Dialysis at (804) 272-0179. This dialysis clinic is managed and/or owned by Davita. Davita - Hioaks Dialysis has the following ownership type - Profit. It was first certified by medicare in February, 1991. The medicare id for this facility is 492556 and it accepts patients under medicare ESRD program.
| Name | Davita - Hioaks Dialysis |
|---|---|
| Location | 671 Hioaks Rd, Richmond, Virginia |
| No. of Dialysis Stations | 16 |
| Medicare ID | 492556 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 671 Hioaks Rd, Richmond, Virginia, 23225 | |
| (804) 272-0179 | |
News Archive
In this post in the ONE Blog, John Anner, president of the East Meets West Foundation, discusses how the foundation is helping to improve sanitation and hygiene practices among poor populations.
Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI® in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
Leading health experts today [Friday 26 September] urge EU Member States to "mobilise all possible resources" to assist West Africans in controlling the Ebola epidemic, in an open letter published in The Lancet.
NanoBio Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M.
› Verified 2 days ago
| NPI Number | 1558325704 |
| Organization Name | Hioaks Dialysis |
| Doing Business As | Dva Healthcare Renal Care Inc |
| Address | 671 Hioaks Rd Richmond, Virginia, 23225 |
| Phone Number | (804) 272-0179 |
News Archive
In this post in the ONE Blog, John Anner, president of the East Meets West Foundation, discusses how the foundation is helping to improve sanitation and hygiene practices among poor populations.
Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI® in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
Leading health experts today [Friday 26 September] urge EU Member States to "mobilise all possible resources" to assist West Africans in controlling the Ebola epidemic, in an open letter published in The Lancet.
NanoBio Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M.
› Verified 2 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 62% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 11% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 27% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 59% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 21% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 20% | 14% |
News Archive
In this post in the ONE Blog, John Anner, president of the East Meets West Foundation, discusses how the foundation is helping to improve sanitation and hygiene practices among poor populations.
Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI® in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
Leading health experts today [Friday 26 September] urge EU Member States to "mobilise all possible resources" to assist West Africans in controlling the Ebola epidemic, in an open letter published in The Lancet.
NanoBio Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M.
› Verified 2 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 49% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 21% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 30% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 42% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 34% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 24% | 12% |
News Archive
In this post in the ONE Blog, John Anner, president of the East Meets West Foundation, discusses how the foundation is helping to improve sanitation and hygiene practices among poor populations.
Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI® in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
Leading health experts today [Friday 26 September] urge EU Member States to "mobilise all possible resources" to assist West Africans in controlling the Ebola epidemic, in an open letter published in The Lancet.
NanoBio Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M.
› Verified 2 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 77% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 23% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 50% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 28% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 22% | 12% |
News Archive
In this post in the ONE Blog, John Anner, president of the East Meets West Foundation, discusses how the foundation is helping to improve sanitation and hygiene practices among poor populations.
Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI® in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
Leading health experts today [Friday 26 September] urge EU Member States to "mobilise all possible resources" to assist West Africans in controlling the Ebola epidemic, in an open letter published in The Lancet.
NanoBio Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M.
› Verified 2 days ago
| Dialysis patients with Hemoglobin data | 98 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 13 |
News Archive
In this post in the ONE Blog, John Anner, president of the East Meets West Foundation, discusses how the foundation is helping to improve sanitation and hygiene practices among poor populations.
Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI® in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
Leading health experts today [Friday 26 September] urge EU Member States to "mobilise all possible resources" to assist West Africans in controlling the Ebola epidemic, in an open letter published in The Lancet.
NanoBio Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M.
› Verified 2 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 102 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 785 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
In this post in the ONE Blog, John Anner, president of the East Meets West Foundation, discusses how the foundation is helping to improve sanitation and hygiene practices among poor populations.
Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI® in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
Leading health experts today [Friday 26 September] urge EU Member States to "mobilise all possible resources" to assist West Africans in controlling the Ebola epidemic, in an open letter published in The Lancet.
NanoBio Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M.
› Verified 2 days ago
| Adult patients getting regular peritoneal dialysis at the center | 126 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 1060 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 93 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
In this post in the ONE Blog, John Anner, president of the East Meets West Foundation, discusses how the foundation is helping to improve sanitation and hygiene practices among poor populations.
Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI® in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
Leading health experts today [Friday 26 September] urge EU Member States to "mobilise all possible resources" to assist West Africans in controlling the Ebola epidemic, in an open letter published in The Lancet.
NanoBio Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M.
› Verified 2 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Davita - Hioaks Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 246 |
| Hypercalcemia patient months | 2026 |
| Patients with Serumphosphor | 254 |
| Patients with Serumphosphor less than 3.5 mg/dL | 11 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 27 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 35 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 17 |
| Patients with Serumphosphor greater than 7 mg/dL | 11 |
News Archive
In this post in the ONE Blog, John Anner, president of the East Meets West Foundation, discusses how the foundation is helping to improve sanitation and hygiene practices among poor populations.
Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI® in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
Leading health experts today [Friday 26 September] urge EU Member States to "mobilise all possible resources" to assist West Africans in controlling the Ebola epidemic, in an open letter published in The Lancet.
NanoBio Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M.
› Verified 2 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 93 |
| Patient months included in arterial venous fistula and catheter summaries | 714 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 77 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 7 |
News Archive
In this post in the ONE Blog, John Anner, president of the East Meets West Foundation, discusses how the foundation is helping to improve sanitation and hygiene practices among poor populations.
Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI® in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
Leading health experts today [Friday 26 September] urge EU Member States to "mobilise all possible resources" to assist West Africans in controlling the Ebola epidemic, in an open letter published in The Lancet.
NanoBio Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M.
› Verified 2 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 183 |
| Hospitalization Rate in facility | 211.5 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 302.5 |
| Hospitalization Rate: Lower Confidence Limit | 156.1 |
News Archive
In this post in the ONE Blog, John Anner, president of the East Meets West Foundation, discusses how the foundation is helping to improve sanitation and hygiene practices among poor populations.
Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI® in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
Leading health experts today [Friday 26 September] urge EU Member States to "mobilise all possible resources" to assist West Africans in controlling the Ebola epidemic, in an open letter published in The Lancet.
NanoBio Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M.
› Verified 2 days ago
The rate of readmission show you whether patients who were being treated regularly at Davita - Hioaks Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 26.4 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 35.3 |
| Readmission Rate: Lower Confidence Limit | 18.7 |
News Archive
In this post in the ONE Blog, John Anner, president of the East Meets West Foundation, discusses how the foundation is helping to improve sanitation and hygiene practices among poor populations.
Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI® in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
Leading health experts today [Friday 26 September] urge EU Member States to "mobilise all possible resources" to assist West Africans in controlling the Ebola epidemic, in an open letter published in The Lancet.
NanoBio Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M.
› Verified 2 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Davita - Hioaks Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .4 (As Expected) |
| SIR: Upper Confidence Limit | 1.31 |
| SIR: Lower Confidence Limit | .07 |
News Archive
In this post in the ONE Blog, John Anner, president of the East Meets West Foundation, discusses how the foundation is helping to improve sanitation and hygiene practices among poor populations.
Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI® in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
Leading health experts today [Friday 26 September] urge EU Member States to "mobilise all possible resources" to assist West Africans in controlling the Ebola epidemic, in an open letter published in The Lancet.
NanoBio Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M.
› Verified 2 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Davita - Hioaks Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 159 |
| Transfusion Rate in facility | 64.3 (Worse than Expected) |
| Transfusion Rate: Upper Confidence Limit | 100.7 |
| Transfusion Rate: Lower Confidence Limit | 43.4 |
News Archive
In this post in the ONE Blog, John Anner, president of the East Meets West Foundation, discusses how the foundation is helping to improve sanitation and hygiene practices among poor populations.
Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI® in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
Leading health experts today [Friday 26 September] urge EU Member States to "mobilise all possible resources" to assist West Africans in controlling the Ebola epidemic, in an open letter published in The Lancet.
NanoBio Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M.
› Verified 2 days ago
The rate of mortality show you whether patients who were being treated regularly at Davita - Hioaks Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 990 |
| Mortality Rate in facility | 19.6 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 23.5 |
| Mortality Rate: Lower Confidence Limit | 16.3 |
News Archive
In this post in the ONE Blog, John Anner, president of the East Meets West Foundation, discusses how the foundation is helping to improve sanitation and hygiene practices among poor populations.
Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI® in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
Leading health experts today [Friday 26 September] urge EU Member States to "mobilise all possible resources" to assist West Africans in controlling the Ebola epidemic, in an open letter published in The Lancet.
NanoBio Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M.
› Verified 2 days ago
News Archive
In this post in the ONE Blog, John Anner, president of the East Meets West Foundation, discusses how the foundation is helping to improve sanitation and hygiene practices among poor populations.
Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI® in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
Leading health experts today [Friday 26 September] urge EU Member States to "mobilise all possible resources" to assist West Africans in controlling the Ebola epidemic, in an open letter published in The Lancet.
NanoBio Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M.
› Verified 2 days ago